Chronic kidney disease: A public health priority and harbinger of premature cardiovascular disease

Journal of Internal Medicine

Volumn 268, Issue 5, 2010, Pages 456-467

  Stenvinkel, P ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cardiovascular disease; Chronic kidney disease; Dialysis; Inflammation

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BICARBONATE; CALCIMIMETIC AGENT; CALCIUM CARBONATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FARNOQUINONE; FOLIC ACID; FOSINOPRIL; GAMMA TOCOPHEROL; GHRELIN; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ROSUVASTATIN; SEVELAMER; SIMVASTATIN; SODIUM THIOSULFATE; TESTOSTERONE; VITAMIN B COMPLEX; VITAMIN D;

ACIDOSIS; ANEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; OBESITY; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RENAL REPLACEMENT THERAPY; REVIEW;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COST OF ILLNESS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; PREVALENCE; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WORLD HEALTH;

EID: 77958600480     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02269.x     Document Type: Review

References (98)

1. Wen CP, Cheng TY, Tsai MK et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008; 371: 2173-82.
2. Safarinejad MR. The epidemiology of adult chronic kidney disease in a population-based study in Iran: prevalence and associated risk factors. J Nephrol 2009; 22: 99-108.
3. Imai E, Horio M, Watanabe T et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009; 13: 621-30.
4. Shan Y, Zhang Q, Liu Z, Hu X, Liu D. Prevalence and risk factors associated with chronic kidney disease in adults over 40 years: a population study from Central China. Nephrology 2010; 15: 354-61.
5. Hemmelgarn BR, Manns BJ, Lloyd A et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423-9.
6. Varma PP, Raman DK, Ramakrishnan TS, Singh P, Varma A. Prevalence of early stages of chronic kidney disease in apparently healthy central government employees in India. Nephrol Dial Transplant 2010; 25: 3011-7.
7. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-47.
8. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification and stratification. Ann Intern Med 2003; 139: 137-47.
9. Hallan SI, Coresh J, Astor BC et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 2275-84.
10. Stevens PE, O'Donoghue DJ, De Lusignan S et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007; 72: 92-9.
11. Zhang Q-L, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008; 8: 117.
12. Lamb EJ, Tomson CR, Roderick PJ. Estimating kidney function in adults using formulae. Ann Clin Biochem 2005; 42: 321-45.
13. Keith DS, Nichols GA, Gullion CM, Betz Brown J, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-63.
14. Hsu CY, Vittinghoff E, Lin F, Shlipak MG. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004; 141: 95-101.
15. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 2003; 14: 2902-7.
16. Kuo HW, Tsai SS, Tiao MM, Yang CY. Epidemiological features of CKD in Taiwan. Am J Kidney Dis 2007; 49: 46-55.
17. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go As. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144: 21-8.
18. Foley RN, Wang C, Snyder JJ, Collins AJ. Cystatin C Levels in U.S. Adults, 1988-1994 Versus 1999-2002: NHANES. Clin J Am Soc Nephrol 2009; 4: 965-72.
19. Fehrman-Ekholm I, Skeppholm L. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 2004; 38: 73-7.
20. Hossain MP, Goyder EC, Rigby JE, El Nahas M. CKD and powerty: a growing global challenge. Am J Kidney Dis 2009; 53: 166-74.
21. Perico N, Codreanu I, Schieppati A, Remuzzi G. Prevention of progression and remission/regression strategies for chronic renal diseases: can we do better now than five years ago? Kidney Int 2005; 98: S21-4.
22. Muntner P, Coresh J, Powe NR, Klag MJ. The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease. J Am Soc Nephrol 2003; 14: 1568-77.
23. Guh JY, Chen HC, Tsai JF, Chuang LY. Herbal therapy is associated with the risk of CKD in adults not using analgesics in Taiwan. Am J Kidney Dis 2007; 49: 626-33.
24. Soderland P, Lovekar S, Weiner DE, Brooks DR, Kaufman JS. Chronic kidney disease associated with environmental toxins and exposures. Adv Chronic Kidney Dis 2010; 17: 254-64.
25. Muntner P, Coresh J, Klag MJ, Whelton PK, Pernerger TV. Exposure to radiologic contrast media and an increased risk of treated end-stage renal disease. Am J Med Sci 2003; 326: 353-9.
26. Baurmeister U, Vienken J, Ward RA. Should dialysis modalities be designed to remove specific uremic toxins? Semin Dial 2009; 22: 454-7.
27. Stenvinkel P, Heimbürger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-911.
28. Bleyer AJ, Russell GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. Kidney Int 1999; 55: 1553-9.
29. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998; 32(Suppl 5): S112-9.
30. Lindner A, Charra B, Sherrard DJ, Schribner BH. Accelerated atherosclerosis in prolonged maintenance haemodialysis. N Engl J Med 1974; 290: 697-701.
31. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lamiere N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-56.
32. Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002; 62: 1402-7.
33. Buzello M, Törnig J, Faulhaber J, Ehmke H, Ritz E, Amann K. The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 2003; 14: 311-6.
34. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69.
35. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
36. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med 2006; 166: 1884-91.
37. Stenvinkel P, Ketteler M, Johnson RJ et al. Interleukin-10, IL-6 and TNF-a: important factors in the altered cytokine network of end-stage renal disease - the good, the bad and the ugly. Kidney Int 2005; 67: 1216-33.
38. Weiner DE, Tighiouart H, Elsayed EF et al. Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int 2008; 73: 1406-12.
39. Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC, Coresh J. Changes in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol 2009; 20: 2617-24.
40. Rifkin DE, Shlipak MG, Katz R et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 2008; 168: 2212-8.
41. Lafrance JP, Miller DR. Acute kidney injury associates with increased long-term mortality. J Am Soc Nephrol 2010; 21: 345-52.
42. Rifkin DE, Katz R, Chonchol M et al. Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. Nephrol Dial Transplant 2010; 25: 1560-7.
43. Elsayed EF, Tighiouart H, Griffith J et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007; 167: 1130-6.
44. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-39.
45. Szummer K, Lundman P, Jacobson SH et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med 2010; 268: 40-9.
46. Acikel S, Yildirir A, Aydinalp A et al. Incidence of aspirin resistance and its relationship with cardiovascular risk factors and graft function in renal transplant recipients. Transplant Proc 2008; 40: 3485-8.
47. Soveri I, Ärnlöv J, Berglund L, Lind L, Fellström B, Sundström J. Kidney function and discrimination of cardiovascular risk in middle-aged men. J Intern Med 2009; 266: 406-13.
48. Holzmann MJ, Ivert T, Jungner I et al. Renal function assessed by two different formulas and incidence of myocardial infarction and death in middle-aged men and women. J Intern Med 2010; 267: 367-9.
49. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-309.
50. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-20.
51. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-9.
52. Locatelli FM-MA, Hannedouche T, Loureiro A et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20: 645-54.
53. Cano NJ, Fouque D, Roth H et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am Soc Nephrol 2007; 18: 2583-91.
54. Jamison RL, Hartigan P, Kaufman JS et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease. JAMA 2007; 10: 1163-70.
55. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
56. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48.
57. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-407.
58. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-61.
59. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int 2003; 84(Suppl): S207-10.
60. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-24.
61. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-7.
62. Cooper BA, Branley P, Bulfone L et al. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010; 363: 609-19.
63. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-90.
64. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-98.
65. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-84.
66. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-32.
67. Kopple JD, Cheung AK, Christiansen JS et al. OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients. Clin J Am Soc Nephrol 2008; 6: 1741-51.
68. Novak JE, Inrig JK, Patel UD, Califf RM, Szczech LA. Negative trials in nephrology: what can we learn? Kidney Int 2008; 74: 1121-7.
69. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-21.
70. Fouque D, Kalantar-Zadeh K, Kopple J et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2007; 73: 391-8.
71. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant of uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-38.
72. Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 2001; 19: 53-61.
73. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, Wu DY. Reverse epidemiology: a spurious hypothesis or a hardcore reality? Blood Purif 2005; 23: 57-63.
74. Tonelli M, Isles C, Curhan GC et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110: 1557-63.
75. Saravanan P, Freeman G, Davidson NC. Risk assessment for sudden cardiac death in dialysis patients: how relevant are conventional cardiac risk factors? Int J Cardiol 2009. [Epub ahead of print].
76. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81: 543-54.
77. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-82.
78. Chmielewski MCJ, Qureshi AR, Axelsson J et al. Temporal discrepancies in the association between the apoB/apoA-I ratio and mortality in incident dialysis patients. J Intern Med 2009; 265: 708-16.
79. Suliman ME, Barany P, Kalantar-Zadeh K, Lindholm B, Stenvinkel P. Homocysteine in uraemia - a puzzling and conflicting story. Nephrol Dial Transplant 2005; 20: 16-21.
80. Madero M, Sarnak MJ, Wang X et al. Body mass index and mortality in CKD. Am J Kidney Dis 2007; 50: 404-11.
81. Wang A, Woo J, Wai Kei C et al. Is a single time-point C-reactive protein predictive of outcome in peritoneal dialysis patients? Am J Kidney Dis 2003; 14: 1871-9.
82. Kaizu Y, Ohkawa S, Odamaki M et al. Association between inflammatory mediators and muscle mass in long-term hemodialysis patients. Am J Kidney Dis 2003; 42: 295-302.
83. Eustace JA, Astor B, Muntner PM, Ikizler TA, Coresh J. Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int 2004; 65: 1031-40.
84. Stenvinkel P, Diczfalusy U, Lindholm B, Heimbürger O. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased mortality in patients on renal replacement therapy. Nephrol Dial Transplant 2004; 19: 972-6.
85. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in end stage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-8.
86. Tepel M, Van Der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure. Circulation 2003; 107: 992-5.
87. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease - what have we learned in 10 years? Semin Dial. 2010 (in press).
88. Himmelfarb J, Phinney S, Ikizler TA, Kane J, McMonagle E, Miller G. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Ren Nutr 2007; 17: 296-304.
89. Hsu SP, Wu MS, Yang CC et al. Chronic green tea extract supplementation reduces hemodialysis-enhanced production of hydrogen peroxide and hypochlorous acid, atherosclerotic factors, and proinflammatory cytokines. Am J Clin Nutr 2007; 86: 1539-47.
90. Fanti P, Asmis R, Stephenson TJ, Sawaya BP, Franke AA. Positive effect of dietary soy in ESRD patients with systemic inflammation - correlation between blood levels of the soy isoflavones and the acute-phase reactants. Nephrol Dial Transplant 2006; 21: 2239-46.
91. Matias PJ, Jorge C, Ferreira C et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010; 5: 905-11.
92. Caglar K, Yilmaz MI, Saglam M et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008; 3: 61-8.
93. Carrero JJ, Stenvinkel P. Of persistent inflammation as a catalyst for other risk factors in chronic kidney disease. A hypothesis proposal. Clin J Am Soc Nephrol 2009; 4: S49-55.
94. McMurray JJ, Kjekshus J, Gullestad L et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009; 120: 188-96.
95. Smith MP, Banks RE, Wood SL, Lewington AJ, Selby PJ. Application of proteomic analysis to the study of renal diseases. Nat Rev Nephrol 2009; 12: 701-12.
96. Luttropp K, Lindholm B, Carrero JJ et al. Genetics/genomics in chronic kidney disese - towards personalized medicine? Semin Dial 2009; 22: 417-22.
97. Zoccali C, Testa A, Spoto B, Tripepi G, Mallamaci F. Mendelian randomization: a new approach to studying epidemiology in ESRD. Am J Kidney Dis 2006; 47: 332-41.
98. Stenvinkel P, Ekström T. Epigenetics - a helpful tool to better understand processes in clinical nephrology? Nephrol Dial Transplant 2008; 23: 1493-6.